Trending

24/7 MN (AMEX: AIM) AIM IMMUNOTECH INC. shares have perked up more than 16% in pre-market trading on light volume and less than 1,000 trades as the company announces additional patients for its studies.

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

https://finance.yahoo.com/news/aim-immunotech-reports-additional-patient-120500825.html

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist